You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY22 is not expected to be complete until September, 2023.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. Eye-readable Solution-based Dye Displacement Probe for Large-area Detection of Opioids

    SBC: Intelligent Optical Systems, Inc.            Topic: CBD20AT001

    Intelligent Optical Systems, Inc., in collaboration with Bowling Green State University, proposes to develop a field-rugged, eye-readable indicating spray solution that can immediately detect synthetic opioids over a large area of contamination (i.e., military vehicles, individual protective equipment, clandestine labs, etc.). The proposed chemosensor in a spray solution format will detect multipl ...

    STTR Phase I 2021 Department of DefenseOffice for Chemical and Biological Defense
  2. Algorithm Performance Evaluation with Low Sample Size

    SBC: Signature Research, Inc.            Topic: NGA20C001

    The team of Signature Research, Inc. and Michigan Technological University will develop and demonstrate methods and metrics to evaluate the performance of machine learning-based computer vision algorithms with low numbers of samples of labeled EO imagery. We will use the existing xView panchromatic dataset to demonstrate a proof-of-concept set of tools. If successful, in Phase II, we will extend t ...

    STTR Phase I 2021 Department of DefenseNational Geospatial-Intelligence Agency
  3. Development of a Therapeutic Monoclonal Antibody Against EGFL6, a Mediator of Tumor Growth and Metastasis

    SBC: Tradewind BioScience            Topic: 102

    SUMMARY A diagnosis of ovarian cancer (OvCa) is especially devastating. With 22,240 diagnoses in 2018 and an estimated 14,070 deaths, OvCa has the third-highest mortality rate, leading to the fifth-highest number of cancer deaths among women in the United States. The objective of this research is to validate the anti-tumor function of humanized antibodies with the end goal of identifying and devel ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  4. Multi-stable Compliant-Mechanism-based Mattress for Bedsore Prevention

    SBC: K MEDICAL, LLC            Topic: NINR

    Abstract Pressure ulcers or decubitus ulcers, more commonly known as bedsores are a huge problem affecting 2.5 million patients every year in the US and causes 60,000 deaths every year. Pressures exceeding 32 mm of Hg in the bony prominences in the back of the patient body lead to bedsores. Despite the existing low air loss mattresses, alternating pressure mattresses and the state-of-the-art air f ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  5. Automated Mental Health Referral System

    SBC: MiResource, Inc.            Topic: 104

    This proposal addresses a significant barrier to obtaining treatment for college-ageyouth with mental disorders. Many college-age youth with impairing mental disordersremain untreated because of concerns about stigma and privacy, inconvenience and wait times, andbecause universities are often unable to service all such students. Also, of critical importance,when referral for treatment is implement ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  6. Multiplexed CRISPR-based immune cell RNA profiling by flow and mass cytometry

    SBC: Dahlia Biosciences, inc.            Topic: NIAID

    Project Summary/Abstract Immune cell profiling is crucial towards understanding key changes in host immune cell subpopulations and functions underlying SARS-CoV-2 viral clearance and immune-mediated pathology. This data will be essential towards the urgent development of COVID-19 diagnostics, therapeutics, and vaccines. Recent publications have showcased the power of scRNA-Seq immune cell profilin ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  7. Mitigation of Ionizing Irradiation-Induced Intestinal Damage by Second-Generation Probiotics LR-IL-22 and LR-IFN-β

    SBC: Chromologic LLC            Topic: R

    Abstract We have developed genetically modified second-generation probiotics for the localized delivery of known mitigators to the GI tract in order to reduce damage and regenerate tissue after exposure to ionizing radiation. Mitigating the effects of ionizing radiation exposure is critical for improving survival in the event of a radiological or nuclear (RAD-NUC) incident, where exposure could le ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  8. Memory-promoting Ad vaccine for long-lived protection against SARS-CoV-2

    SBC: TENDEL THERAPIES INC.            Topic: NIAID

    This grant will establish immunologic proof-of-concept for a second-generation SARS-CoV-2 vaccine providing extraordinarily durable T-cell and antibody responses, which together protect the respiratory mucosa and minimize the risk of antibody-dependent enhancement (ADE). The vaccine platform combines the immunostimulatory power and proven safety of adenovirus-vectored vaccines with novel in- vecto ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  9. Leveraging an academic-industry partnership to develop a cancer-specific mobile meditation app

    SBC: Calm.com, Inc.            Topic: 102

    1 Project Summary/Abstract2 Approximately 15.5 million US cancer patients/survivors experience a host of residual symptoms (e.g.,3 fatigue, anxiety, depression, pain, sleep disturbance) and reduced quality of life that are often not resolved with4 even the best-available current standard of care therapies. Residual symptom burden impairs cancer survivor5 functioning and leads to increased rates of ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  10. HBI-002 to Treat Parkinson’s Disease

    SBC: Hillhurst Biopharmaceuticals, Inc.            Topic: 107

    PROJECT SUMMARY The goal of the proposed project is to evaluate the potential of HBI-002, a novel oral formulation of carbon monoxide (CO), as a neuroprotective agent in Parkinson’s disease (PD). A growing body of research suggests that low doses of CO - and the heme oxygenase (HO) enzymes that generate endogenous CO - protect against neuronal cell loss in PD, and epidemiologic studies have asso ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government